Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan's Ruling Party Considers New Drug Administrative Body

This article was originally published in PharmAsia News

Executive Summary

Facing the aftermath of the hepatitis C scandal, Japan's ruling Liberal Democratic Party organized a discussion panel on pharmaceutical policy, and the panel has proposed to establish a new administrative entity to oversee drug approval and adverse effects prevention. Currently, the Ministry of Health, Labor and Welfare, and the Pharmaceuticals and Medical Device Agency are in charge of drug review, approval and safety measures. The LDP panel is proposing to establish an independent drug administrative agency that is separate from MHLW, functioning like a Japanese version of U.S. FDA. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts